表紙
市場調査レポート

認知障害:世界の治験レビュー

Cognitive Disorders Global Clinical Trials Review, H2, 2015

発行 GlobalData 商品コード 196103
出版日 ページ情報 英文 1052 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
認知障害:世界の治験レビュー Cognitive Disorders Global Clinical Trials Review, H2, 2015
出版日: 2015年12月16日 ページ情報: 英文 1052 Pages
概要

当レポートでは、認知障害の治療薬に関する治験動向について、治験数および被験者数、段階別・相別の状況、有望企業、開発中の治療薬の情報などをまとめ、概略以下の構成でお届けします。

イントロダクション

地域別の治験動向

  • 国別の治験動向
    • アジア太平洋地域の主要国
    • 欧州の主要国

段階別の治験状況

  • 進行中の治験

相別の治験状況

一定期間に採用された被験者

有望なスポンサー

有望な治療薬の比較

治験プロファイル

  • 主要企業の治験概要
    • Dr. Willmar Schwabe GmbH & Co. KG
    • GlaxoSmithKline plc
  • 主要大学/研究所/病院の治験概要
    • Fundacion para la Investigacion y Formacion en Ciencias de la Salud
    • Centre Hospitalier Universitaire, Amiens
    • Northumbria University
    • Mahidol University
    • Medical Research Council
    • The University of Queensland
    • Saarland University Hospital
    • University Hospital, Angers
    • UMC Utrecht

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3107CTIDB

GlobalData's clinical trial report, "Cognitive Disorders Global Clinical Trials Review, H2, 2015" provides an overview of Cognitive Disorders clinical trials scenario. This report provides top line data relating to the clinical trials on Cognitive Disorders. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Cognitive Disorders to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Cognitive Disorders to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Cognitive Disorders Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Cognitive Disorders Therapeutics, Global, Clinical Trials by Region, 2015*
  • Cognitive Disorders Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Cognitive Disorders Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Europe, Top Five Countries, 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, North America, Top Countries, 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2015*
  • Proportion of Cognitive Disorders to Central Nervous System Clinical Trials, G7 Countries (%), 2015*
  • Cognitive Disorders Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Cognitive Disorders Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Cognitive Disorders to Central Nervous System Clinical Trials, E7 Countries (%), 2015*
  • Cognitive Disorders Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Cognitive Disorders Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Cognitive Disorders Therapeutics, Global, Clinical Trials by Phase, 2015*
  • Cognitive Disorders Therapeutics, Global, Clinical Trials In Progress by Phase 2015*
  • Cognitive Disorders Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Cognitive Disorders Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*

List of Figures

  • Cognitive Disorders Therapeutics, Global, Clinical Trials by Region (%), 2015*
  • Cognitive Disorders Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Cognitive Disorders Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, North America, Top Countries (%), 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2015*
  • Proportion of Cognitive Disorders to Central Nervous System Clinical Trials, G7 Countries (%), 2015*
  • Cognitive Disorders Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Cognitive Disorders Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Cognitive Disorders to Central Nervous System Clinical Trials, E7 Countries (%), 2015*
  • Cognitive Disorders Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Cognitive Disorders Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Cognitive Disorders Therapeutics, Global, Clinical Trials by Phase (%), 2015*
  • Cognitive Disorders Therapeutics, Global, Clinical Trials In Progress by Phase, 2015*
  • Cognitive Disorders Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Cognitive Disorders Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Cognitive Disorders Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • GlobalData Methodology
Back to Top